Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was approved by the FDA in 2015 to reverse the anesthesia-induced neuromuscular ...

The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Treatment with inebilizumab was associated with continued improvement in patients with AChR+ generalized myasthenia gravis, according to 52-week results from the MINT trial.